|
Cholesterol-Lowering Program Update
|
26 June 2023 at 10:20am
|
|
Brain Injury Program Preclinical Development Update
|
9 June 2023 at 8:45am
|
|
Cholesterol-Lowering Program Preclinical Studies Completed
|
26 May 2023 at 9:10am
|
|
Quarterly Activities Report and Appendix 4C
|
26 April 2023 at 8:45am
|
|
Cholesterol-Lowering Program Preclinical Development Update
|
11 April 2023 at 8:50am
|
|
Nyrada Half Year Results FY2023
|
24 February 2023 at 11:10am
|
|
Appendix 4D and Half Year Report to 31 December 2022
|
24 February 2023 at 11:10am
|
|
Quarterly Activities Report and Appendix 4C
|
30 January 2023 at 8:55am
|
|
Collaboration with Walter Reed and UNSW Extended to 2025
|
18 January 2023 at 9:00am
|
|
Notification of cessation of securities - NYR
|
16 January 2023 at 4:45pm
|
|
Brain Injury Program Update
|
11 January 2023 at 8:45am
|
|
Results of Meeting
|
21 November 2022 at 12:30pm
|
|
AGM Presentation by James Bonnar CEO
|
21 November 2022 at 8:45am
|
|
Nyrada AGM 2022 Chairmans Address
|
21 November 2022 at 8:45am
|
|
Nyrada Receives A$1.2M R&D Tax Incentive Rebate
|
18 November 2022 at 8:45am
|
|
CEO Remuneration Update
|
27 October 2022 at 8:40am
|
|
Quarterly Activities Report and Appendix 4C
|
26 October 2022 at 8:55am
|
|
2022 AGM Letter to Shareholders and Proxy
|
18 October 2022 at 10:10am
|
|
2022 AGM Notice of Meeting and Proxy
|
18 October 2022 at 10:00am
|
|
Efficacy Study Published in Journal of Lipid Research
|
10 October 2022 at 8:40am
|
|
Presentation to ShareCafe Hidden Gems Webinar
|
29 September 2022 at 8:30am
|
|
Presentation to E&P Small Caps Health Care Conference
|
5 September 2022 at 8:50am
|
|
Nyrada Reports Full Year FY2022 Results
|
29 August 2022 at 6:40pm
|
|
Annual Report to June 30 2022
|
29 August 2022 at 6:35pm
|
|
Preliminary Final Report
|
29 August 2022 at 6:30pm
|
|
Appendix 4G and Corporate Governance Statement
|
29 August 2022 at 6:30pm
|
|
Nyrada Board Changes
|
2 August 2022 at 8:45am
|
|
Initial Director's Interest Notice - GM
|
2 August 2022 at 8:40am
|
|
Final Director's Interest Notice - PM
|
2 August 2022 at 8:40am
|
|
Quarterly Activities Report and Appendix 4C
|
26 July 2022 at 9:30am
|
|
Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis
|
20 July 2022 at 8:45am
|
|
Cholesterol-Lowering Program Update
|
29 June 2022 at 10:05am
|
|
Corporate Presentation
|
7 June 2022 at 9:35am
|
|
Brain Injury Program Target Unveiled and Phase I Update
|
6 June 2022 at 8:45am
|
|
European Patent to be Granted for Cholesterol-Lowering Drug
|
17 May 2022 at 9:10am
|
|
Nyrada Quarterly Activities Report & Appendix 4C
|
19 April 2022 at 9:55am
|
|
Investor Roadshow Presentation
|
30 March 2022 at 8:45am
|
|
New Drug Offers Potential Oral Treatment for Concussion
|
29 March 2022 at 8:55am
|
|
Presentation to Meet the CEO Life Sciences Edition
|
2 March 2022 at 9:25am
|
|
Nyrada Half Year Results FY2022
|
25 February 2022 at 2:05pm
|
|
Appendix 4D and Half Year Report to 31 December 2021
|
25 February 2022 at 2:05pm
|
|
Nyrada Quarterly Activities Report & Appendix 4C
|
21 January 2022 at 8:40am
|
|
Application for quotation of securities - NYR
|
17 January 2022 at 2:05pm
|
|
Change of Director's Interest Notice - ID
|
17 January 2022 at 2:00pm
|
|
Change of Director's Interest Notice - MF
|
17 January 2022 at 2:00pm
|
|
Change of Director's Interest Notice - RW
|
17 January 2022 at 2:00pm
|
|
Change of Director's Interest Notice - JM
|
17 January 2022 at 2:00pm
|
|
Change of Director's Interest Notice - CC
|
17 January 2022 at 2:00pm
|
|
Change of Director's Interest Notice - PM
|
17 January 2022 at 2:00pm
|
|
Nyrada Receives A$1.3M R&D Tax Incentive Rebate
|
12 January 2022 at 10:15am
|
Nyrada Inc